For Jessica Lescault there is no question that her 6-year-old English bulldog Moose deserves cutting-edge biotechnology cancer treatment as much as any human patient.
"Pets are your loved ones, pets should be your family, pets are not something you keep on a chain in the backyard," said the intensive-care nurse from Somers, Connecticut.
Lescault, 43, who enrolled Moose in a clinical trial of an experimental drug designed to help his immune system fight his cancer, represents the type of pet lover that has spurred animal health companies around the globe to invest in developing complex new treatments previously reserved for humans.